Coronavirus disease 2019 and gastrointestinal disorders in children

Abstract

During the past 3 years, the coronavirus disease 2019 (COVID-19) pandemic has had a great impact on people all over the world. However, it has become evident that disease manifestations and severity differ across age groups. Most children have a milder disease course than adults but possibly more pronounced gastrointestinal (GI) symptoms. Given the child’s developing immune system, the impact of COVID-19 on disease development may differ compared to adults. This study reviews the potential bi-directional relationship between COVID-19 and GI diseases in children, focusing on common pediatric conditions such as functional GI disorders (FGID), celiac disease (CeD), and inflammatory bowel disease (IBD). Children with GI diseases, in general, and CeD and IBD, in particular, do not seem to have an increased risk of severe COVID-19, including risks of hospitalization, critical care need, and death. While infections are considered candidate environmental factors in both CeD and IBD pathogenesis, and specific infectious agents are known triggers for FGID, there is still not sufficient evidence to implicate COVID-19 in the development of either of these diseases. However, given the scarcity of data and the possible latency period between environmental triggers and disease development, future investigations in this field are warranted.

Keywords

celiac disease COVID-19 functional gastrointestinal disorder inflammatory bowel disease

Introduction

In December 2019, a novel coronavirus, later named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged and spread rapidly throughout the world.^1–6 In March 2020, the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) pandemic, and as of January 27, 2023, over 752 million confirmed cases have been reported worldwide.^5,7

SARS-CoV-2, a single-stranded RNA virus, commonly causes fever, cough, sore throat, runny nose, loss of smell or taste, and headache.^1,8 A more severe disease course may result in pneumonia or respiratory and multiorgan failure.^1,8 By January 27, 2023, the WHO dashboard reported 6,804,491 deaths from COVID-19, mainly in older adults, with a very low risk of death in children and younger people.⁷ In contrast to infected adults, most children and adolescents have only experienced mild disease symptoms.^7,9–12

Although considered a respiratory disease, children and adults with COVID-19 frequently report gastrointestinal (GI) complaints (e.g. diarrhea, nausea, vomiting, and abdominal pain).^13–16 Similarly, GI manifestations are prominent features of the multisystem inflammatory syndrome in children (MIS-C).^17,18 MIS-C is a severe hyperinflammatory condition that can follow a COVID-19 infection in children and often requires aggressive treatment.^17,19

Because SARS-CoV-2 can infect most parts of the GI tract,²⁰ there has been a concern that the virus may influence the incidence of GI diseases and their disease course (or vice versa), such that patients with GI diseases may have an increased susceptibility to and risk of severe COVID-19. These questions were also raised for children often susceptible to respiratory viral infections and where viral encounters may imprint on their developing immune system.²¹

This study reviews evidence of potential bi-directional relationships between COVID-19 and pediatric GI diseases. While hepatic and pancreatic manifestations have been described in children with COVID-19,^{14,16,22–24} this review focuses on more common digestive disorders in children, such as functional GI disorders (FGIDs), celiac disease (CeD), and inflammatory bowel disease (IBD). We also review data on changed diagnostic work-up and management of children with GI diseases during and after the pandemic.

COVID-19 and the gastrointestinal tract

COVID-19 usually causes respiratory symptoms in the upper and lower airways, as well as fever, headache, myalgia, and loss of smell and taste.^1–3,8 However, GI complaints have also become common, especially in the pediatric population.^15,20,25

SARS-CoV-2 can affect the GI system in several ways. The viral spike protein binds to membrane receptors, mediating a fusion between the virus and the membrane. Research has demonstrated that angiotensin-converting enzyme 2 (ACE2) receptor and transmembrane serine protease 2 (TMPRSS2) are crucial in this process. The ACE2 receptor and the TMPRSS2 are co-expressed not only in the lungs but also in the esophageal, gastric, and small and large intestinal mucosa, making the entire GI tract highly susceptible to SARS-CoV-2 infection.^{13,14,20,26–28} Of note, it seems that the expression of these proteins varies across ages. With increasing age, ACE2 and TMPRSS2 expressions decrease in the GI tract while increasing in the lungs.²⁹ This finding may partly explain the noticeably milder disease course in children than in adults and perhaps age-related differences in COVID-19 symptomatology overall.

Once the virus has entered the cell, new virions are synthesized and assembled. Afterward, they are released into the GI tract, causing direct damage to the enterocyte and viral shedding in the stool.^13,26,30,31 Fecal excretion of SARS-CoV-2 is common.^14,26 In an early study from China Hua et al. detected SARS-CoV-2 RNA in feces in 32/35 (91%) infected children, with viral shedding persisting up to 70 days.³¹ This finding was confirmed in a 2022 meta-analysis reporting a pooled prevalence of fecal SARS-CoV-2 RNA in almost 9 of 10 infected children and 7 of 10 children who had turned negative in the respiratory specimen.³⁰

Viral damage of the enterocytes may increase intestinal permeability and release of inflammatory mediators (e.g., interleukin 2 and tumor necrosis factor-alpha). These cytokines may induce GI symptoms and systemic inflammation.^13,20 Furthermore, SARS-CoV-2 can alter the intestinal microbiota.³² Through immunological crosstalk between the gut and lungs (the gut-lung axis), a changing gut microbiome may also occur when the GI tract is not directly infected by the virus.^13,33

Gastrointestinal manifestations

Soon into the pandemic, a Chinese study reported clinical features of 651 hospitalized patients with COVID-19 (average age 46 years), with 11% having at least one GI symptom (nausea, vomiting, or diarrhea).³⁴ Since then, similar or even higher rates of GI complaints have been reported in adult patients with COVID-19. A North American study including 1992 patients across 36 centers reported GI symptoms in up to 53% of the participants, with diarrhea being most frequently observed.²⁵

GI complaints may be more common in children with COVID-19 than in adults,^10,15,35 although comparisons are difficult given the heterogeneity of compared study populations. In contrast to adults, children with COVID-19 usually have a mild disease course that rarely requires medical attention.^11,12 Whether the study cohorts constitute inpatients, outpatients, or household contacts will probably significantly impact the resolution and weighting of reported symptoms.

The Chinese Pediatric Novel Coronavirus Study Team assessed children who had been in contact with individuals with known or suspected COVID-19 in early 2020.³⁶ Of 1391 tested children, 171 were SARS-CoV-2 positive (median age 6.7 years). Almost 16% of infected children were asymptomatic, but 9% reported diarrhea and 6% vomiting.³⁶ The Peds COVID-19 Registry, a US study of >6000 hospitalized children³⁷ reported vomiting in 13% of the cohort, abdominal pain in 10%, and diarrhea in 11% of infected children. Several reviews and meta-analyses have reported diarrhea in 2-33%, nausea or vomiting in 5–35%, and abdominal pain in 4–35%.^14,16,38 Still, individual studies have reported a higher frequency of GI complaints, including GI symptoms in >50% of children in a North American multicenter study of severe pediatric COVID-19.²⁵ These high numbers are in analogy with other viral infections (e.g., influenza); where children more frequently report GI symptoms than adults.³⁹

Multisystem inflammatory syndrome in children

Multisystem inflammatory syndrome in children (MIS-C) has proven to be one of the most serious COVID-19 manifestations in children and adolescents.⁴⁰ MIS-C is a hyperinflammatory syndrome with multiorgan dysfunction seen in individuals <21 years of age with a recent history of COVID-19.⁴¹ Next to fever (mandatory criteria), GI symptoms are among the most predominant clinical manifestations of MIS-C, demonstrated in >90% of the patients.^{17,18,41–48} While diarrhea and vomiting seem to be the most common symptoms of MIS-C, abdominal pain, described in one-third of the affected children, is the most noticeable symptom, and often severe enough to warrant radiology or even surgery.^43,48,49 This GI predominance of MIS-C differs from Kawasaki’s disease, a distinct infectious-related hyperinflammatory syndrome with usually no or only mild GI symptoms.^50–52 Initially, MIS-C was associated with a significant mortality rate, particularly in low- and middle-income countries.^53,54 However, with timely recognition of the condition and the development of improved anti-inflammatory treatment protocols, the morbidity and mortality rates of MIS-C have been reversed.¹⁹ Likewise, when patients are provided anti-inflammatory treatment, GI symptoms of MIS-C often resolve within a few weeks.^17,43,52

Celiac disease

Celiac disease (CeD) is a chronic autoimmune enteropathy precipitated by gluten intake in genetically predisposed individuals.⁵⁵ The only available treatment for CeD is a strict gluten-free diet (GFD).⁵⁶ In children, the prevalence of CeD is approximately 1% worldwide and possibly higher in Nordic countries.^56,57 Human leukocyte antigen haplotype DQ2 or DQ8 is necessary but insufficient for CeD development.^55,58 Besides gluten, other environmental factors contribute to CeD. Although the timing and nature of such environmental factors are largely unknown,^55,58 multiple studies have acknowledged the implication of infections in disease pathogenesis.^59–64 Conversely, CeD patients may also be susceptible to infectious diseases.^65–68

Celiac disease and risk of COVID-19

Over the past decades, CeD has consistently been associated with an increased risk of sepsis and infections with encapsulated bacteria (e.g., invasive pneumococcal disease and pneumonia).^66,68–71 These risks likely relate to the higher prevalence of functional hyposplenism and splenic atrophy in patients with CeD.⁷² However, also increased intestinal permeability,^73,74 altered intestinal microbiota,^75,76 and impaired nutritional status^77,78 may predispose celiac patients to infections. In this connection, pediatric and adult celiac patients have been linked to an increased risk of nonencapsulated serious infections,⁶⁵ including a twofold risk of severe influenza.⁷⁹ Although the susceptibility to serious infections seems to persist after introducing a GFD, the risk is likely somewhat higher in untreated CeD.⁶⁵

Children with CeD do not seem to have an increased risk of symptomatic COVID-19. A population-based Swedish cohort study of 4490 patients with childhood-onset CeD observed no hospital admissions due to COVID-19 between February and July 2020 (and only one COVID-19-related hospitalization in 21,736 general population comparators).⁸⁰ Similar null findings have been reported from Italy⁸¹ and a large international study in which pediatric and adult CeD patients had no significantly increased risk of COVID-19 [odds ratio 1.18 for laboratory-confirmed COVID-19, 95% confidence interval (CI) = 0.75–1.84].⁸² Additional international data from the Surveillance Epidemiology Under Research Exclusion for Celiac Disease (SECURE-CELIAC) Registry, collected between March 31, 2020, and February 23, 2021, have also confirmed hospitalization and fatality rates for children and adults to be similar in CeD compared to the general population.⁸³ Also adult studies have unequivocally shown a similar incidence of COVID-19 in CeD as in the general population.^84–86 Likewise, a large US study (TriNETX) found no significantly increased risk of hospital admission, critical care, or death from COVID-19.⁸⁷

COVID-19 and risk of subsequent celiac disease

Numerous viruses have been suggested to be involved in the development of CeD.⁶³ In prospective studies, intestinal viruses, including rotavirus, enterovirus, and parechovirus infections, have been linked to an increased risk of CeD or CeD autoimmunity (i.e., CeD serology positivity).^{59,63,88–90} Moreover, several respiratory viral infections (e.g., influenza⁶⁰ and respiratory syncytial virus⁶¹) have been associated with later CeD.^63,91,92

The role of viruses in CeD pathogenesis remains to be elucidated. Still, they might contribute to the immunological loss of gluten tolerance through, for example, bystander activation or by increasing gut permeability, enabling epithelial translocation of gluten, or through increased expression of CeD-specific tissue transglutaminase.^64,93–96 Both are critical elements in the pathogenesis of CeD. Likewise, induction of proinflammatory interferons from viral infections, including SARS-CoV-2, has been hypothesized to predispose to CeD.⁹⁷

Data on COVID-19 and the subsequent risk of CeD are so far limited. A recent study from Türkiye reported a threefold increase in the annual number of CeD diagnoses in children during the pandemic (March 2020 through June 2021, n = 47) compared to the years before the pandemic (January 2008 through February 2020, n = 148).⁹⁸ Of the 47 patients diagnosed during the pandemic, endoscopy was performed in 33 (70%). Although moderate-severe mucosal lesions (>Marsh 3a) were less common during the pandemic compared to the prepandemic years (42% versus 82%), the proportion of patients with classical CeD (e.g., diarrhea and poor growth) seemed to increase during the pandemic. Although this finding was not statistically significant, a potentially harmful delay in CeD diagnosis has been reported by other authors.⁹⁹ Nevertheless, the interpretation of the results from the Turkish study⁹⁸ is restricted by the retrospective nature of the data and the limited sample size. The potentially harmful delay in the diagnosis of CeD was reported in Italy.⁹⁹ Italy had a very strict COVID-19 lockdown, particularly at the pandemic’s beginning. A recent Italian study demonstrated a 14% reduction in newly diagnosed CeD during the pandemic.¹⁰⁰ The authors attributed this reduction to the diminished availability of health care services and possibly the fear of contracting COVID-19. Still, they could not entirely rule out the influence of other pathogenic factors or a natural fluctuation in CeD incidence.¹⁰⁰ However, a prospective German study found that adult patients exposed to mild COVID-19 infection had persistent higher levels of CD-specific anti-tissue transglutaminase antibodies (compared to uninfected blood donors), also months after the infectious period, perhaps indicating a future rise in CeD incidence.¹⁰¹

COVID-19 and adherence to a GFD

The COVID-19 pandemic has significantly impacted food supply chains, but supply disruptions have varied between countries. A US survey of 378 households of children with CeD reported decreased availability of gluten-free foods and an increase in intentional gluten intake.¹⁰² Difficulties in maintaining a strict GFD during the pandemic have also been reported in India.¹⁰³ In contrast, reports from Italy and Türkiye have suggested unchanged GFD adherence levels of children with CeD.^104,105

IBD

IBD, consisting mainly of two conditions, Crohn’s disease (CD) and ulcerative colitis, is a chronic, complex, and costly immune-mediated inflammatory disease. Although most IBD patients are diagnosed in early adulthood, it is estimated that some 15% of all patients are diagnosed during childhood.¹⁰⁶ The global incidence of childhood-onset IBD has increased significantly over the past few decades, with the highest IBD risks reported in Northern Europe and Canada.¹⁰⁷ While genetic susceptibility plays a role in IBD,^108,109 this rapid rise of childhood-onset IBD also suggests an important role of early environmental elements, where one candidate risk factor for IBD is infections.^110–112 Moreover, a significant risk of disease- and treatment-associated infectious complications has also been observed in the modern immunomodulatory IBD treatment era.¹¹³

IBD and risk of COVID-19

Children and adults with IBD have an increased risk of serious infections.^113,114 Opportunistic, skin, and GI infections are among those that may pose problems for patients with IBD.¹¹⁵ There are numerous factors contributing to the infection susceptibility of IBD. First, vast immunological and genetic data have linked IBD development to an aberrant immune response (including the innate and adaptive immune systems), which alterations may also predispose to infections.¹¹⁶ Second, IBD-related bowel surgery and medical therapies for IBD, which suppress the immune system, are risk factors for severe infections.^117,118 The highest risks of serious infections have been observed in IBD patients exposed to combinations of immunomodulatory drugs, especially those including corticosteroids.^115,119

Early in the pandemic, concerns of an increased risk of COVID-19 and a more severe disease course in patients with IBD were raised. Part of that concern related to the immunosuppressive effect of many IBD-related drugs,¹¹⁵ but was also grounded in the fact that SARS-CoV-2 enters human cells via the ACE2 receptor, expressed on epithelial and endothelial cells of the GI tract,^20,28 and up-regulated during inflammation. Hence, longitudinal studies have examined whether IBD patients are at risk of COVID-19 or severe COVID-19.

A recent comprehensive meta-analysis found no significant overall increased pooled relative risk (RR) of COVID-19 in IBD (RR 0.47, 95% CI 0.18–1.26) or across IBD subtypes.¹²⁰ Instead, some data suggest a lower risk of COVID-19 in adult IBD patients compared to non-IBD patients,^121,122 a phenomenon that might be related to ‘COVID shielding’, that is, patients with chronic conditions may take extra precautions to reduce the risk of infection.¹²³ Several studies have reported fears and over-protection in children with IBD compared to their peers.^124–127

Although a recent meta-analysis concluded no overall increased risk of COVID-19 hospitalization in IBD,¹²⁸ individual adult studies have shown a higher risk of COVID-19 hospitalization in IBD patients compared to general population comparators, but with RR estimates varying considerably from an increase of 17–68%.^121,129,¹³⁰ Furthermore, in adults with IBD severe COVID-19 has mostly been observed in those of older age and with cardiovascular comorbidities.¹³¹

The age-related risk of COVID-19 hospitalization in IBD patients has been illustrated in the SECURE-IBD Registry. In this registry, where some 800 of more than 7000 reports concerned pediatric IBD, COVID-19 hospitalization rates ranged from 5% in 10 to 19-year-olds to 47% in those ⩾80 years.¹³² Also, reports to a European IBD database suggest a mild disease course of COVID-19 in children with IBD.¹³³

Rates of severe COVID-19 (e.g. critical care admission or death) in IBD have been similar to those of the general population.^120,129,134 Propensity-score matched data from US healthcare organizations showed adult IBD patients to have an incidence rate ratio of 0.85 (95% CI 0.69–1.06) for critical care needs after COVID-19 infection compared to the general population.¹²² The COVID-19 mortality rate appears similar in people with and without IBD.^120,122 As expected, case fatality for inpatients with IBD is primarily confined to older patients and those having comorbidities. In contrast, few deaths have been reported in pediatric IBD patients. The mortality rate of children <19 years in the SECURE-IBD Registry is 0%.¹³²

Evidence in adults with IBD suggests that corticosteroids, but not biologicals, were associated with adverse outcomes to COVID-19.^122,135,136 Pooled estimates from a recent meta-analysis linked corticosteroid use with a nearly twofold increase in RR for hospitalization and a threefold risk of critical care need or death.¹²⁰ These results have prompted expert consensus recommendations to perform individual risk-benefit assessments of COVID-19 severity and IBD activity and consider gradual tapering of systemic corticosteroids and switch to budesonide in IBD patients who test positive for SARS-CoV-2.¹³⁷

Finally, besides case reports,^137,138 neither pediatric IBD nor its treatment seems linked to the COVID-19-associated hyperinflammatory syndrome MIS-C.¹³⁹

COVID-19 and risk of subsequent IBD

Childhood infections have been suggested to impact the risk of IBD development, possibly mediated through perturbations of the gut microbiome.¹⁴⁰ Infections are also important determinants for the maturation of the immune system and maintenance of mucosal barrier integrity.¹⁴¹ Various forms of gastroenteritis have been consistently shown to increase the risk of IBD.¹⁴² However, in early childhood also, respiratory infections have been associated with up to a three times higher risk of pediatric IBD.¹⁴³ We also know that respiratory infections, the predominant infectious subtype of young children worldwide, usually cause GI manifestations in early life³⁹ and influence the intestinal microbiome.³³

A US study with data on 587 pediatric IBD cases showed an increased incidence of pediatric IBD diagnoses during the COVID-19 pandemic compared to the expected number based on historic time trend data.¹⁴⁴ In contrast, the most extensive study of some 4300 IBD patients reported a lower risk of incident IBD following SARS-CoV-2 compared to a propensity-score matched cohort who tested negative for SARS-CoV-2 (RR 0.63; 95% CI: 0.58–0.70).¹²² The lower IBD incidence post-COVID remained essentially unchanged when restricted to IBD diagnosed >6 months after testing for COVID-19.¹²² The same study showed that IBD patients with COVID-19 were 1.3 times more likely to have a flare (defined by IBD-related hospitalization) at a 3-month follow-up than those without prior COVID-19 (6.77% versus 5.08%, p < 0.01; RR 1.33, 95% CI 1.18–1.51).¹²² Still, another large adult IBD study reported no significant impact of COVID-19 on clinical IBD activity.¹⁴⁵

COVID-19 and adherence to IBD treatment

Patients with IBD have been reported to continue to adhere to their medication regimens during the COVID-19 pandemic.^124,125,127

FGID

FGIDs are common in children and consist of various disorders believed to be associated with the GI tract but without structural or biochemical abnormality findings at routine examinations. According to the Rome IV criteria from 2016, pediatric FGIDs could be divided into over 15 subdiagnoses. The most common subtypes are irritable bowel syndrome, functional abdominal pain, constipation, and dyspepsia.^146,147 While the etiology of FGIDs is undetermined, several factors proposed to be relevant to its pathophysiology,¹⁴⁸ including increased intestinal permeability, dysbiosis, and immune functioning, have also been linked to COVID-19 and other infections.

COVID-19 and risk of subsequent functional gastrointestinal disorder

An increasingly recognized subset of patients develops FGID after a GI infection. This association has mainly been studied in adult patient cohorts with laboratory-confirmed gastroenteritis, though the results have also been confirmed in some cohorts of children with GI infection.^149–152 In particular, bacterial enteritis (e.g., salmonella, campylobacter, and shigella) and parasite infections (e.g., giardia) seem to enhance the risk of FGID.^151,153,154 Research on viral infections and postinfectious FGID in children is limited. A 2009 study examining rotavirus infection as a potential trigger for chronic GI complaints of children in the US and Italy found a higher, albeit not statistically significant, prevalence of functional abdominal pain after rotavirus infection compared to controls (16% versus 7%, p = 0.31).¹⁵⁵

New-onset GI symptoms have been reported in adults who have recovered from COVID-19¹⁵⁶ but have yet to be observed in recovering children.¹⁵⁷ A recently published study from India found that 36/320 (11%) adults with COVID-19 developed FGID-like symptoms at a 1-month follow-up; symptoms remained in some 7% of the COVID-19 patients at 6 months of follow-up.¹⁵⁸ Moderate to severe COVID-19 and the presence of GI symptoms at the time of infection were negative predictors for persistent long-term FGID-like symptoms.¹⁵⁸

Long COVID (also known as postacute COVID syndrome) refers to the potential long-term effects of COVID-19, including fatigue, dyspnea, and cognitive problems that persist or return at least 3 months after the onset of COVID-19. While this condition has primarily been reported in adults, systematic reviews suggest that long COVID may also occur in children and adolescents.^159,160 However, GI symptoms of long COVID are usually not predominant but may represent up to 2% of affected children.^160,161

COVID-19 and pediatric gastroenterology practices

Related to the generally milder disease course in children than in adults with COVID-19, pediatric health care, compared to adult care, has been less impacted by the pandemic. Still, routines to practice pediatric care, including pediatric gastroenterology, have been affected.¹⁶² For example, the pandemic necessitated a rapid adaptation to remote care delivery,^163,164 and a rise in virtual care for chronic GI conditions (e.g. IBD¹⁶⁵ and CeD¹⁶⁶). While patient satisfaction with virtual care is typically reported to be high,¹⁶⁴ and its use has been linked to reduced travel costs and school absences, the effectiveness of virtual GI clinics has not been thoroughly studied. Also, physical examination and growth monitoring, important features of clinical decision-making, are typically not part of remote care.

The pandemic has had repercussions on digestive endoscopy in adults,¹⁴⁵ but even more so in children, where for safety and comfort concerns, endoscopy is recommended to be performed under general anesthesia or deep sedation.¹⁶⁷ Because the pandemic consumed almost all anesthetic support on a worldwide scale, pediatric gastroenterologists had to adapt to a clinical praxis with a significantly reduced capacity to perform endoscopic procedures essential to the assessment, treatment, and care of children with many GI conditions (e.g., CeD, eosinophilic esophagitis, and IBD).¹⁶⁸ To counter the effects of reduced endoscopy capacity, pediatric papers suggested temporary reductions in required immunoglobulin A anti-tissue transglutaminase antibody thresholds for nonbiopsy-verified CeD diagnoses.¹⁶⁹ In addition, there has likely been an increase in nonendoscopic monitoring of IBD activity, such as fecal calprotectin testing. Still, the effects on care quality related to the modified pediatric endoscopy practice remain largely unknown. The restrictions associated with the COVID-19 pandemic have also had a negative impact on pediatric gastroenterology training programs in North America and Europe.^170,171

Finally, the COVID-19 pandemic spurred a rapid set-up of studies and surveillance registers of different patient groups (e.g., CeD and IBD patients).^83,132 While these registers have mainly focused on adults, their data include children and adolescents, which has enabled updated information on COVID-19 risks and real-time data to support management and treatment decisions.

Comments

In summary, the risk of contracting and being seriously ill with COVID-19 seems comparable for children with CeD or IBD as for the general population.

Also, so far no firm evidence links COVID-19 with an increased risk of CeD, IBD, or FGID. Still, 3 years into the COVID-19 pandemic, its potential impact on CeD, IBD, and FGID has not been fully determined. Speculatively, there may be a long latency period between infectious exposures and the possible development of these diseases. Hence, given the ongoing intense spread of SARS-CoV-2 worldwide, the potential bi-directional association between COVID-19 and pediatric GI conditions needs further investigation. The pandemic might also have resulted in delayed GI diagnosis: families with children with GI complaints might have avoided hospitals for fear of contracting the virus.^124–127 The reduced endoscopic capacity might have delayed the work-up of those symptoms.¹⁴⁵

This review discusses the evidence of the development or exacerbation of pediatric GI conditions amidst COVID-19. However, we acknowledge that the COVID-19 pandemic has also carried a significant mental health burden on children globally,¹⁷² which may be even greater in children with chronic illness.¹⁷³

The COVID-19 pandemic significantly impaired pediatric gastroenterology training programs and hampered our capacity to diagnose and follow children with GI complaints endoscopically. The pandemic’s effects on pediatric gastroenterology practices could last for years. On the other hand, concerted efforts and investments to combat delayed training and backlogs can likely limit these adverse effects.

Footnotes

Acknowledgements

None.

Declarations

ORCID iD

Anna Röckert Tjernberg

References

Huang

Wang

, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506.

Chen

Zhou

Dong

, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507–513.

Zhu

Zhang

Wang

, et al. A novel coronavirus from patients with pneumonia in China, 2019. New Engl J Med 2020; 382: 727–733.

Holshue

DeBolt

Lindquist

, et al. First case of 2019 novel Coronavirus in the United States. New Engl J Med 2020; 382: 929–936.

World Health Organization. Timeline: WHO’s COVID-19 response. Geneva: WHO, 2022.

World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. Geneva: WHO, 2022.

World Health Organization. WHO coronavirus (COVID-19) dashboard. Geneva: WHO.

Long

Carius

Chavez

, et al. Clinical update on COVID-19 for the emergency clinician: presentation and evaluation. Am J Emerg Med 2022; 54: 46–57.

O’Driscoll

Ribeiro Dos Santos

Wang

, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 2021; 590: 140–145.

10.

Waterfield

Watson

Moore

, et al. Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study. Arch Dis Child 2021; 106: 680–686.

11.

Dong

, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020; 145: 20200316.

12.

Liu

, et al. Children with COVID-19 behaving milder may challenge the public policies: a systematic review and meta-analysis. BMC Pediatr 2020; 20: 410.

13.

Calitri

Fumi

Ignaccolo

, et al. Gastrointestinal involvement in paediatric COVID-19 – from pathogenesis to clinical management: a comprehensive review. World J Gastroenterol 2021; 27: 3303–3316.

14.

Pegoraro

Trapani

Indolfi

. Gastrointestinal, hepatic and pancreatic manifestations of COVID-19 in children. Clin Res Hepatol Gastroenterol 2022; 46: 101818.

15.

Tian

Rong

Nian

, et al. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther 2020; 51: 843–851.

16.

Wang

Yuan

. Digestive system symptoms and function in children with COVID-19: A meta-analysis. Medicine 2021; 100: e24897.

17.

Feldstein

Rose

Horwitz

, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. New Engl J Med 2020; 383: 334–346.

18.

Dufort

Koumans

Chow

, et al. Multisystem inflammatory syndrome in children in New York State. New Engl J Med 2020; 383: 347–358.

19.

McArdle

Vito

Patel

, et al. Treatment of multisystem inflammatory syndrome in children. New Engl J Med 2021; 385: 11–22.

20.

Lei

Ding

Nie

, et al. Potential effects of SARS-CoV-2 on the gastrointestinal tract and liver. Biomed Pharmacother 2021; 133: 111064.

21.

Jain

. The early life education of the immune system: moms, microbes and (missed) opportunities. Gut Microbes 2020; 12: 1824564.

22.

Hwaiz

Merza

Hamad

, et al. Evaluation of hepatic enzymes activities in COVID-19 patients. Int Immunopharmacol 2021; 97: 107701.

23.

Antala

Diamond

Kociolek

, et al. Severe hepatitis in pediatric Coronavirus Disease 2019. J Pediatr Gastroenterol Nutr 2022; 74: 631–635.

24.

Zhu

Yuan

, et al. Clinical and immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in Wuhan, China. JAMA Netw Open 2020; 3: e2010895–20200601.

25.

Elmunzer

Spitzer

Foster

. Digestive manifestations in patients hospitalized with Coronavirus disease 2019. Clin Gastroenterol Hepatol 2021; 19: 1355–1365.e1354.

26.

Sansotta

Norsa

D’Antiga

. Gastrointestinal coronavirus disease 2019 manifestations in childhood. Curr Opin Clin Nutr Metab Care 2022; 25: 195–202.

27.

Mohamed

Ghoneim

Abu-Risha

, et al. Gastrointestinal and hepatic diseases during the COVID-19 pandemic: manifestations, mechanism and management. World J Gastroenterol 2021; 27: 4504–4535.

28.

Harmer

Gilbert

Borman

, et al. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002; 532: 107–110.

29.

Schurink

Roos

Vos

, et al. ACE2 protein expression during childhood, adolescence, and early adulthood. Pediatr Dev Pathol 2022; 25: 404–408.

30.

Benvari

Mahmoudi

Mohammadi

. Gastrointestinal viral shedding in children with SARS-CoV-2: a systematic review and meta-analysis. World J Pediatr 2022; 18: 582–588.

31.

Hua

Miao

Zheng

, et al. Epidemiological features and viral shedding in children with SARS-CoV-2 infection. J Med Virol 2020; 92: 2804–2812.

32.

Liu

Zhu

, et al. Gastrointestinal disturbance and effect of fecal microbiota transplantation in discharged COVID-19 patients. J Med Case Rep 2021; 15: 60–20210208.

33.

Budden

Gellatly

Wood

, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol 2017; 15: 55–63.

34.

Jin

Lian

, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020; 69: 1002–1009.

35.

Al-Beltagi

Saeed

Bediwy

, et al. Paediatric gastrointestinal disorders in SARS-CoV-2 infection: epidemiological and clinical implications. World J Gastroenterol 2021; 27: 1716–1727.

36.

Zhang

, et al. SARS-CoV-2 infection in children. New Engl J Med 2020; 382: 1663–1665.

37.

Ashktorab

Brim

Pizuorno

, et al. COVID-19 pediatric patients: gastrointestinal symptoms, presentations, and disparities by race/ethnicity in a large, multicenter US Study. Gastroenterology 2021; 160: 1842–1844.

38.

Bolia

Dhanesh Goel

Badkur

, et al. Gastrointestinal manifestations of pediatric Coronavirus disease and their relationship with a severe clinical course: a systematic review and meta-analysis. J Trop Pediatr 2021; 67: fmab05.

39.

Minodier

Charrel

Ceccaldi

, et al. Prevalence of gastrointestinal symptoms in patients with influenza, clinical significance, and pathophysiology of human influenza viruses in faecal samples: what do we know? Virol J 2015; 12: 215–20151212.

40.

García-Salido

de Carlos Vicente

Belda Hofheinz

, et al. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Crit Care 2020; 24: 666–20201126.

41.

Waseem

Shariff

Tay

, et al. Multisystem inflammatory syndrome in children. J Emerg Med 2022; 62: 28–37.

42.

Godfred-Cato

Bryant

Leung

, et al. COVID-19-Associated multisystem inflammatory syndrome in children – United States, March-July 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 1074–1080.

43.

Sahn

Eze

Edelman

, et al. Features of intestinal disease associated with COVID-Related multisystem inflammatory syndrome in children. J Pediatr Gastroenterol Nutr 2021; 72: 384–387.

44.

Torres

Izquierdo

Acuña

, et al. Multisystem inflammatory syndrome in children (MIS-C): Report of the clinical and epidemiological characteristics of cases in Santiago de Chile during the SARS-CoV-2 pandemic. Int J Infect Dis 2020; 100: 75–81.

45.

Bautista-Rodriguez

Sanchez-de-Toledo

Clark

, et al. Multisystem inflammatory syndrome in children: an international survey. Pediatrics 2021; 147: 20201124.

46.

Rostami-Maskopaee

Ladomenou

Razavi-Amoli

, et al. Clinical characteristics and outcomes of the multisystem inflammatory syndrome in children (MIS-C) following COVID-19 infection in Iran: a multicenter study. PLoS One 2022; 17: e0274104–20220922.

47.

Sayed

Bhalala

Strom

, et al. Gastrointestinal manifestations in hospitalized children with acute SARS-CoV-2 infection and multisystem inflammatory condition: an Analysis of the VIRUS COVID-19 registry. Pediatr Infect Dis J 2022; 41: 751–758.

48.

Radia

Williams

Agrawal

, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr Respir Rev 2021; 38: 51–57.

49.

Rouva

Vergadi

Galanakis

. Acute abdomen in multisystem inflammatory syndrome in children: a systematic review. Acta Paediatr 2022; 111: 467–472.

50.

Sharma

Ganigara

Galeotti

, et al. Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol 2021; 17: 731–748.

51.

Otar Yener

Paç Kısaarslan

Ulu

, et al. Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study. Rheumatol Int 2022; 42: 879–889.

52.

Bar-Meir

Guri

Godfrey

, et al. Characterizing the differences between multisystem inflammatory syndrome in children and Kawasaki disease. Sci Rep 2021; 11: 13840–20210705.

53.

Davies

Evans

Kanthimathinathan

, et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet 2020; 4: 669–677.

54.

Acevedo

Piñeres-Olave

Niño-Serna

, et al. Mortality and clinical characteristics of multisystem inflammatory syndrome in children (MIS-C) associated with covid-19 in critically ill patients: an observational multicenter study (MISCO study). BMC Pediatr 2021; 21: 516.

55.

Ludvigsson

Leffler

Bai

, et al. The Oslo definitions for coeliac disease and related terms. Gut 2013; 62: 43–52.

56.

Caio

Volta

Sapone

, et al. Celiac disease: a comprehensive current review. BMC Med 2019; 17: 142.

57.

Myléus

Ivarsson

Webb

, et al. Celiac disease revealed in 3% of Swedish 12-year-olds born during an epidemic. J Pediatr Gastroenterol Nutr 2009; 49: 170–176.

58.

Lebwohl

Sanders

Green

PHR

. Coeliac disease. Lancet 2018; 391: 70–81.

59.

Oikarinen

Puustinen

Lehtonen

, et al. Enterovirus infections are associated with the development of celiac disease in a birth cohort study. Front Immunol 2021; 11: 604529.

60.

Kårhus

Gunnes

Størdal

, et al. Influenza and risk of later celiac disease: a cohort study of 2.6 million people. Scand J Gastroenterol 2018; 53: 15–23.

61.

Tjernberg

Ludvigsson

. Children with celiac disease are more likely to have attended hospital for prior respiratory syncytial virus infection. Dig Dis Sci 2014; 59: 1502–1508. 2014.

62.

Beyerlein

Donnachie

Ziegler

. Infections in early life and development of celiac disease. Am J Epidemiol 2017; 186: 1277–1280.

63.

Størdal

Kahrs

Tapia

, et al. Review article: exposure to microbes and risk of coeliac disease. Aliment Pharmacol Ther 2021; 53: 43–62.

64.

Sánchez

Hoffmanová

Szczepanková

, et al. Contribution of infectious agents to the development of celiac disease. Microorganisms 2021; 9: 547.

65.

Röckert Tjernberg

Mårild

Söderling

, et al. Celiac disease and serious infections: A nationwide cohort study from 2002 to 2017. Am J Gastroenterol 2022; 117: 1675–1683.

66.

Ludvigsson

Olén

Bell

, et al. Coeliac disease and risk of sepsis. Gut 2008; 57: 1074–1080.

67.

Zingone

Abdul Sultan

Crooks

, et al. The risk of community-acquired pneumonia among 9803 patients with coeliac disease compared to the general population: a cohort study. Aliment Pharmacol Ther 2016; 44: 57–67.

68.

Simons

Scott-Sheldon

LAJ

Risech-Neyman

, et al. Celiac disease and increased risk of pneumococcal infection: a systematic review and meta-analysis. Am J Med 2018; 131: 83–89.

69.

Canova

Ludvigsson

Baldo

, et al. Risk of bacterial pneumonia and pneumococcal infection in youths with celiac disease – a population-based study. Dig Liver Dis 2019; 51: 1101–1105.

70.

Thomas

Wotton

Yeates

, et al. Pneumococcal infection in patients with coeliac disease. Eur J Gastroenterol Hepatol 2008; 20: 624–628.

71.

Röckert Tjernberg

Bonnedahl

Inghammar

, et al. Coeliac disease and invasive pneumococcal disease: a population-based cohort study. Epidemiol Infect 2017; 145: 1203–1209.

72.

Sabatino

. Is it worth investigating splenic function in patients with celiac disease? World J Gastroenterol 2013; 19: 2313–2318.

73.

Heyman

Abed

Lebreton

, et al. Intestinal permeability in coeliac disease: insight into mechanisms and relevance to pathogenesis. Gut 2012; 61: 1355–1364.

74.

Spadoni

Zagato

Bertocchi

, et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science 2015; 350: 830–834.

75.

Adelman

Woodworth

Langelier

, et al. The gut microbiome’s role in the development, maintenance, and outcomes of sepsis. Crit Care 2020; 24: 278.

76.

Cenit

Olivares

Codoñer-Franch

, et al. Intestinal microbiota and celiac disease: Cause, consequence or co-evolution? Nutrients 2015; 7: 6900–6923.

77.

Kreutz

Adriaanse

MPM

van der Ploeg

EMC

, et al. Narrative review: nutrient deficiencies in adults and children with treated and untreated celiac disease. Nutrients 2020; 12: 20200215.

78.

Katona

Katona-Apte

. The interaction between nutrition and infection. Clin Infect Dis 2008; 46: 1582–1588.

79.

Mårild

Fredlund

Ludvigsson

. Increased risk of hospital admission for influenza in patients with celiac disease: a nationwide cohort study in Sweden. Am J Gastroenterol 2010; 105: 2465–2473.

80.

Lebwohl

Larsson

Söderling

, et al. Risk of severe covid-19 in patients with celiac disease: a population-based Cohort Study. Clin Epidemiol 2021; 13: 121–130.

81.

Lionetti

Fabbrizi

Catassi

. Prevalence of COVID-19 in Italian children with celiac disease: a cross-sectional study. Clin Gastroenterol Hepatol 2021; 19: 1075.

82.

Zhen

Stefanolo

Temprano

, et al. The risk of contracting COVID-19 is not increased in patients with celiac disease. Clin Gastroenterol Hepatol 2021; 19: 391–393.

83.

Uche-Anya

Husby

Kaplan

, et al. An international reporting registry of patients with celiac disease and COVID-19: initial results from SECURE-CELIAC. Clin Gastroenterol Hepatol 2021; 19: 2435–2437.e2434.

84.

Tian

Yang

, et al. Celiac disease and the susceptibility of COVID-19 and the risk of severe COVID-19: a Mendelian randomization study. Clin Transl Gastroenterol 2022; 13: e00480.

85.

Gasbarrini

Dionisi

Corazza

, et al. COVID-19 in celiac disease: a multicentric retrospective cohort study. Eur Rev Med Pharmacol Sci 2021; 25: 4400–4404.

86.

Zingone

D’Odorico

Lorenzon

, et al. Risk of COVID-19 in celiac disease patients. Autoimmun Rev 2020; 19: 102639.

87.

Hadi

Sohail

Lakhani

. Outcomes of SARS-CoV-2 infection in patients with celiac disease: a multicenter research network study. Ann Gastroenterol 2022; 35: 164–168.

88.

Stene

Honeyman

Hoffenberg

, et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol 2006; 101: 2333–2340.

89.

Kahrs

Chuda

Tapia

, et al. Enterovirus as trigger of coeliac disease: nested case-control study within prospective birth cohort. BMJ 2019; 364: l231.

90.

Tapia

Chudá

Kahrs

, et al. Parechovirus infection in early childhood and association with subsequent celiac disease. Am J Gastroenterol 2021; 116: 788–795.

91.

Auricchio

Cielo

de Falco

, et al. Respiratory infections and the risk of celiac disease. Pediatrics 2017; 140: e20164102.

92.

Mårild

Kahrs

Tapia

, et al. Infections and risk of celiac disease in childhood: a prospective nationwide cohort study. Am J Gastroenterol 2015; 110: 1475–1484.

93.

Bouziat

Hinterleitner

Brown

, et al. Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science 2017; 356: 44–50.

94.

Moser

Carter

Schultz-Cherry

. Astrovirus increases epithelial barrier permeability independently of viral replication. J Virol 2007; 81: 11937–11945.

95.

Fasano

Not

Wang

, et al. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease. Lancet 2000; 355: 1518–1519.

96.

Gómez-Rial

Rivero-Calle

Salas

, et al. Rotavirus and autoimmunity. J Infect 2020; 81: 183–189.

97.

Trovato

Montuori

Pietropaoli

, et al. COVID-19 and celiac disease: a pathogenetic hypothesis for a celiac outbreak. Int J Clin Pract 2021; 75: e14452.

98.

Cakir

Guven

Issi

, et al. New-onset celiac disease in children during COVID-19 pandemic. Acta Paediatr 2022; 111: 383–388.

99.

Catassi

Vallorani

Cerioni

, et al. A negative fallout of COVID-19 lockdown in Italy: Life-threatening delay in the diagnosis of celiac disease. Dig Liver Dis 2020; 52: 1092–1093.

100.

Crocco

Calvi

Canzoneri

, et al. The influence of SARS-CoV-2 pandemic on the diagnosis of celiac disease and clinical practice in Pediatric Gastroenterology. Nutrients 2023; 15: 20230121.

101.

Lingel

Meltendorf

Billing

, et al. Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals. J Autoimmun 2021; 122: 102682.

102.

Mehrotra

Weisbrod

, et al. Survey-based study on food insecurity during COVID-19 for households with children on a prescribed gluten-free diet. Am J Gastroenterol 2022; 117: 931–934.

103.

Mehtab

Chauhan

Agarwal

, et al. Impact of Corona Virus Disease 2019 pandemic on adherence to gluten-free diet in Indian patients with celiac disease. Indian J Gastroenterol 2021; 40: 613–620.

104.

Monzani

Lionetti

Felici

, et al. Adherence to the gluten-free diet during the lockdown for COVID-19 pandemic: a web-based survey of Italian subjects with celiac disease. Nutrients 2020; 12: 3467.

105.

Bükülmez

Baş

Çiftci

. Evaluation of anti-COVID-19 measures taken by the parents of children with celiac disease: a cross-sectional study. Sao Paulo medical journal = Revista paulista de medicina 2021; 139: 201–209.

106.

Forss

Clements

Bergman

, et al. A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014. Aliment Pharmacol Ther 2022; 55: 691–699.

107.

Kuenzig

Fung

Marderfeld

, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology 2022; 162: 1147–1159.e1144.

108.

Sazonovs

Stevens

Venkataraman

. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility. Nat Genet 2022; 54: 1275–1283.

109.

Anderson

Boucher

Lees

, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011; 43: 246–252.

110.

Jakobsen

Paerregaard

Munkholm

, et al. Environmental factors and risk of developing paediatric inflammatory bowel disease – a population based study 2007-2009. J Crohns Colitis 2013; 7: 79–88.

111.

Benchimol

Fortinsky

Gozdyra

, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011; 17: 423–439.

112.

Ananthakrishnan

. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015; 12: 205–217.

113.

Ludvigsson

Sachs

Järås

, et al. Serious infections in pediatric inflammatory bowel disease 2002-2017-A nationwide Cohort Study. J Pediatr 2021; 238: 66–73.e61.

114.

Ludvigsson

Holmgren

Grip

, et al. Adult-onset inflammatory bowel disease and rate of serious infections compared to the general population: a nationwide register-based cohort study 2002–2017. Scand J Gastroenterol 2021; 56: 1152–1162.

115.

Kucharzik

Ellul

Greuter

, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis 2021; 15: 879–913.

116.

Irving

Gibson

. Infections and IBD. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 18–27.

117.

Singh

Facciorusso

Dulai

, et al. Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2020; 18: 69–81.e63.

118.

Kirchgesner

Lemaitre

Carrat

, et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology 2018; 155: 337–346.e310.

119.

Borman

Côté-Daigneault

Colombel

. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. Expert Rev Gastroenterol Hepatol 2018; 12: 1101–1108.

120.

Singh

Jena

Kumar-M

, et al. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. United Eur Gastroenterol J 2021; 9: 159–176.

121.

Attauabi

Poulsen

Theede

, et al. Prevalence and outcomes of COVID-19 among patients with inflammatory bowel Disease-A Danish prospective population-based Cohort Study. J Crohns Colitis 2021; 15: 540–550.

122.

Hadi

Dulai

Kupec

, et al. Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: propensity matched research network analysis. Aliment Pharmacol Ther 2022; 55: 191–200.

123.

Cooksey

Underwood

Brophy

, et al. Shielding reduced incidence of COVID-19 in patients with inflammatory arthritis but vulnerability is associated with increased mortality. Rheumatology 2022; 61: SI120–SI128.

124.

Dorfman

Nassar

Binjamin Ohana

, et al. Pediatric inflammatory bowel disease and the effect of COVID-19 pandemic on treatment adherence and patients’ behavior. Pediatr Res 2021; 90: 637–641.

125.

Trindade

Ferreira

. COVID-19 Pandemic’s effects on disease and psychological outcomes of people with inflammatory bowel disease in Portugal: a preliminary research. Inflamm Bowel Dis 2021; 27: 1224–1229.

126.

Reinsch

Stallmach

Grunert

. The COVID-19 pandemic: fears and overprotection in pediatric patients with inflammatory bowel disease and their families. Pediatr Gastroenterol Hepatol Nutr 2021; 24: 65–74.

127.

Grunert

Reuken

Stallhofer

, et al. Inflammatory bowel disease in the COVID-19 pandemic: the Patients’ Perspective. J Crohns Colitis 2020; 14: 1702–1708.

128.

Abdulla

Mohammed

AlQamish

, et al. Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis. Sci Rep 2022; 12: 21333–20221209.

129.

Creemers

Rezazadeh Ardabili

Jonkers

, et al. Severe COVID-19 in inflammatory bowel disease patients in a population-based setting. PLoS One 2021; 16: e0258271.

130.

Ludvigsson

Axelrad

Halfvarson

, et al. Inflammatory bowel disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden. United Eur Gastroenterol J 2021; 9: 177–192.

131.

Lin

Lau

Chanchlani

, et al. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut 2022; 71: 1426–1439.

132.

Brenner

EJUR

Colombel

Kappelman

. SECURE-IBD Database Public Data Update (2022).

133.

Brenner

Pigneur

Focht

, et al. Benign evolution of SARS-Cov2 infections in children with inflammatory bowel disease: results from two international databases. Clin Gastroenterol Hepatol 2021; 19: 394–396.e395.

134.

MacKenna

Kennedy

Mehrkar

. Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatol 2022; 4: e490–e506.

135.

Khan

Mahmud

Trivedi

, et al. Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System. Gut 2021; 70: 1657–1664.

136.

Ungaro

Agrawal

Park

, et al. Autoimmune and chronic inflammatory disease patients with COVID-19. ACR Open Rheumatol 2021; 3: 111–115.

137.

Rubin

Abreu

Rai

, et al. Management of patients with Crohn’s disease and ulcerative colitis during the coronavirus disease-2019 pandemic: Results of an International Meeting. Gastroenterology 2020; 159: 6–13.e16.

138.

Meredith

Khedim

Henderson

, et al. Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 [PIMS-TS] in a patient receiving infliximab therapy for inflammatory bowel disease. J Crohns Colitis 2021; 15: 687–691.

139.

Riphagen

Gomez

Gonzalez-Martinez

, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020; 395: 1607–1608.

140.

Kostic

Xavier

Gevers

. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014; 146: 1489–1499.

141.

Brodin

Davis

. Human immune system variation. Nat Rev Immunol 2017; 17: 21–29.

142.

Axelrad

Olén

Askling

, et al. Gastrointestinal infection increases odds of inflammatory bowel disease in a nationwide case–control study. Clin Gastroenterol Hepatol 2019; 17: 1311–1322 e1317.

143.

Bernstein

Burchill

Targownik

, et al. Events within the first year of life, but not the neonatal period, affect risk for later development of inflammatory bowel diseases. Gastroenterology 2019; 156: 2190–2197.e2110.

144.

Rosenbaum

Ochoa

Hasan

, et al. Epidemiologic assessment of pediatric inflammatory bowel disease presentation in NYC during COVID-19. J Pediatr Gastroenterol Nutr 2023; 76: 622–626.

145.

Amiot

Rahier

Baert

, et al. The impact of COVID-19 on patients with IBD in a prospective European cohort study. J Crohns Colitis 2023; 17: 37–48.

146.

Drossman

. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 2016; 150: 1262–1279.e2.

147.

Hyams

Di Lorenzo

Saps

, et al. Functional disorders: Children and adolescents. Gastroenterology 2016; 9: 20160215.

148.

Aziz

Simrén

. The overlap between irritable bowel syndrome and organic gastrointestinal diseases. Lancet Gastroenterol Hepatol 2021; 6: 139–148.

149.

Hanevik

Dizdar

Langeland

, et al. Development of functional gastrointestinal disorders after Giardia lamblia infection. BMC Gastroenterol 2009; 9: 27.

150.

Pisipati

Connor

Riddle

. Updates on the epidemiology, pathogenesis, diagnosis, and management of postinfectious irritable bowel syndrome. Curr Opin Infect Dis 2020; 33: 411–418.

151.

Cremon

Stanghellini

Pallotti

, et al. Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood. Gastroenterology 2014; 147: 69–77.

152.

Schwille-Kiuntke

Unverdorben

Weimer

, et al. Bacterial infections in childhood: A risk factor for gastrointestinal and other diseases? United Eur Gastroenterol J 2015; 3: 31–38.

153.

Saps

Pensabene

Di Martino

, et al. Post-infectious functional gastrointestinal disorders in children. J Pediatr 2008; 152: 812–816.e811.

154.

Wensaas

Langeland

Hanevik

, et al. Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study. Gut 2012; 61: 214–219.

155.

Saps

Pensabene

Turco

, et al. Rotavirus gastroenteritis: precursor of functional gastrointestinal disorders? J Pediatr Gastroenterol Nutr 2009; 49: 580–583.

156.

Blackett

Jodorkovsky

, et al. Prevalence and risk factors for gastrointestinal symptoms after recovery from COVID-19. Neurogastroenterol Motil 2022; 34: e14251.

157.

Magnusson

Skyrud

Suren

, et al. Healthcare use in 700 000 children and adolescents for six months after covid-19: before and after register based cohort study. BMJ 2022; 376: e066809.

158.

Golla

Vuyyuru

Kante

, et al. Long-term gastrointestinal sequelae following COVID-19: a prospective follow-up Cohort Study. Clin Gastroenterol Hepatol 2023; 21: 789–796.e781.

159.

Ludvigsson

. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr 2021; 110: 914–921.

160.

Lopez-Leon

Wegman-Ostrosky

Ayuzo Del Valle

, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses. Sci Rep 2022; 12: 9950.

161.

Miller

Nguyen

Navaratnam

, et al. Prevalence and characteristics of persistent symptoms in children during the COVID-19 pandemic: Evidence from a household cohort study in England and Wales. Pediatr Infect Dis J 2022; 41: 979–984.

162.

Kriem

Rahhal

. COVID-19 pandemic and challenges in pediatric gastroenterology practice. World J Gastroenterol 2020; 26: 5387–5394.

163.

Wosik

Fudim

Cameron

, et al. Telehealth transformation: COVID-19 and the rise of virtual care. J Am Med Inform Assoc 2020; 27: 957–962.

164.

Dobrusin

Hawa

Gladshteyn

, et al. Gastroenterologists and Patients Report High satisfaction rates with telehealth services during the novel Coronavirus 2019 Pandemic. Clin Gastroenterol Hepatol 2020; 18: 2393–2397.e2392.

165.

Benchimol

Carroll

Geist

, et al. Crohn’s and Colitis Canada’s 2021 impact of COVID-19 and inflammatory bowel disease in Canada: Children and expectant mothers with inflammatory bowel disease. J Can Assoc Gastroenterol 2021; 4: S27–S33.

166.

Månsson

Meijer-Boekel

Mårild

. Utilization and effectiveness of eHealth technology in the follow-up of celiac disease: a systematic review. J Pediatr Gastroenterol Nutr 2022; 74: 812–818.

167.

Lightdale

Walsh

Narula

, et al. Pediatric Endoscopy Quality Improvement Network quality standards and indicators for pediatric endoscopy facilities: A Joint NASPGHAN/ESPGHAN guideline. J Pediatr Gastroenterol Nutr 2022; 74: S16–S29.

168.

Shaoul

Day

. Pediatric Endoscopy during COVID-19 times. Front Pediatr 2021; 9: 750717.

169.

Trovato

Montuori

Cucchiara

, et al. ESPGHAN ‘biopsy-sparing’ guidelines for celiac disease in children with low antitransglutaminase during COVID-19. Eur J Gastroenterol Hepatol 2020; 32: 1523–1526.

170.

Niţă

Tsita

Grima

, et al. Understanding and responding to the impact of COVID-19 on paediatric gastroenterology training & practice of young ESPGHAN members. J Pediatr Gastroenterol Nutr 2021; 73: 592–598.

171.

Mallon

Pohl

Phatak

, et al. Impact of COVID-19 on Pediatric Gastroenterology fellow training in North America. J Pediatr Gastroenterol Nutr 2020; 71: 6–11.

172.

Nearchou

Flinn

Niland

, et al. Exploring the impact of COVID-19 on Mental health outcomes in children and adolescents: a systematic review. Int J Environ Res Public Health 2020; 17: 20201116.

173.

Westbom

. Well-being of children with chronic illness. A population-based study in a Swedish primary care district. Acta Paediatr 1992; 81: 625–629.